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a b s t r a c t
Bone marrow stromal antigen 2 (BST2), an interferon-inducible antiviral factor, has been shown to block
the release of various enveloped viruses from cells. It has also been identiﬁed as an innate immune system
component. Most enveloped viruses subject to BST2 restriction bud at the plasma membrane. Here we
report our ﬁndings that (a) the production of human coronavirus 229E (HCoV-229E) progeny viruses,
whose budding occurs at the ER-Golgi intermediate compartment (ERGIC), markedly decreases in the
presence of BST2; and (b) BST2 knockdown expression results in enhanced HCoV-229E virion production.
Electron microscopy analyses indicate that HCoV-229E virions are tethered to cell surfaces or intracellular
membranes by BST2. Our results suggest that BST2 exerts a broad blocking effect against enveloped virus
release, regardless of whether budding occurs at the plasma membrane or intracellular compartments.
& 2013 Elsevier Inc. All rights reserved.
Introduction
Coronaviruses are found in a wide variety of host species, including
bats, mice, cats, dogs, pigs, horses, birds, whales and humans (Perlman
and Netland, 2009). Infected hosts may develop respiratory, enteric,
hepatic or neurological diseases with different degrees of severity.
Prior to the 2002–2003 severe acute respiratory syndrome (SARS)
outbreak triggered by a previously unknown coronavirus (Drosten
et al., 2003; Marra et al., 2003; Rota et al., 2003), human coronaviruses
(HCoV) 229E and OC43 were recognized as the two primary corona-
viruses causing upper respiratory tract infections associated with
severe pulmonary diseases in elderly, newborn, and immunocompro-
mised individuals (Garbino et al., 2006). Results from one study
involving a large collection of human nasopharyngeal specimens
suggest that HCoV-229E, -NL63, -OC43 and -HKU1 are the only
coronaviruses circulating in human populations (Zlateva et al., 2013).
However, more recent studies of fatal human infections by a novel
SARS-like coronavirus named MERS-CoV have been reported (Zaki
et al., 2012). This is a reminder that novel coronaviruses can emerge
and cause life-threatening infectious diseases, although most human
coronavirus infections result in mild symptoms such as those asso-
ciated with the common cold.
Most virus infections induce a type 1 interferon (IFN-α⧸β) response
that in turn triggers the expression of numerous diverse genes (Sadler
and Williams, 2008). IFN-inducible or IFN-stimulated gene (ISGs)
expression is considered an important innate defense system against
virus infections (Randall and Goodbourn, 2008). Among IFN-inducible
expression factors, BST2 (also known as CD317, HM1.24, or tetherin)
has been characterized as a host restriction factor capable of impeding
the release of multiple viruses, including retroviruses (Gupta et al.,
2009; Jia et al., 2009; Le Tortorec and Neil, 2009; Neil et al., 2008;
Van Damme et al., 2008; Zhang et al., 2009), ﬁloviruses (Jouvenet
et al., 2009; Kaletsky et al., 2009; Sakuma et al., 2009), herpesviruses
(Mansouri et al., 2009), arenaviruses (Radoshitzky et al., 2010), and
inﬂuenza viruses, including virus-like particles (Watanabe et al., 2011;
Yondola et al., 2011) and wild-type virions (Mangeat et al., 2012), and
the Sendai virus (Bampi et al., 2013).
BST2 is a 30–36 kDa type II transmembrane protein consisting of a
cytoplasmic amino-terminal region followed by a transmembrane
domain, a coiled-coil extracellular domain, and a carboxy-terminal
glycosyl-phosphatidylinositol (GPI) anchor (Kupzig et al., 2003). The
protein is known to associate with lipid rafts on cell surfaces and at the
internal membrane, likely with the trans-Golgi network (TGN) (Kupzig
et al., 2003). One model suggests that BST2 inhibits virion release by
tethering nascent virions to cell surfaces via its amino-terminal trans-
membrane domain and carboxy-terminal GPI anchor (Neil et al., 2008;
Perez-Caballero et al., 2009). Treatment with a protease such as
subtilisin can support virion release, presumably via proteolytic BST2
cleavages linking budding virions to cell surfaces (Neil et al., 2006).
Most viruses restricted by BST2 in this manner share two common
features: they possess envelope proteins and bud from the plasma
membrane. Coronavirus assembly and budding occurs at the ER-Golgi
intermediate compartment (ERGIC) (Hunter, 2001). Vesicles contain-
ing accumulated coronavirus particles are transported to the plasma
membrane, where they release virions exocytotically (Masters, 2006).
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The goal of our research was to determine whether BST2 also affects
the release of coronaviruses whose budding processes differ from
those of most other enveloped viruses. We selected HCoV-229E, a
common human coronavirus, as a representative strain. Our results
suggest that BST2 is capable of counteracting HCoV-229E infection via
the tethering of nascent progeny virions at the cell surface. Our data
also support the idea that BST2 is capable of restricting the virus
particle release of different enveloped virus families.
Results
BST2 reduces HCoV-229E virion yields
To determine whether BST2 is also capable of inhibiting human
coronavirus egress, we examined the supernatants of HCoV-229E-
infected HeLa cells following transient BST2 knockdown. As shown
in Fig. 1A, BST2-knockdown HeLa cells yielded higher quantities of
virions compared to control HeLa cells. We then established a stable
BST2 knockdown HeLa cell line (HeLa/BST2-), and observed that it
exerted an effect similar to that of the transient BST2 knockdown in
terms of promoting HCoV-229E production (Fig. 1B). When tested
with a Vpu-deleted HIV-1 clone (known to be restricted by BST2 in
the absence of the Vpu viral protein), the BST2 knockdown resulted
in the release of a larger quantity of virus particles (Fig. 1C); this is
consistent with previous reports (Gofﬁnet et al., 2010; Neil et al.,
2008).
Since IFNα is capable of enhancing BST2 expression, we tested
the impact of IFNα treatment on HCoV-229E replication. HCoV-
229E-infected A549 cells were treated with IFNα. At 24 h post-
treatment, culture supernatants were collected and subjected to
plaque assays and Western immunoblotting. As expected, the IFNα
Fig. 1. BST2 inhibits virion production. (A) HeLa cells were transfected with BST2-speciﬁc siRNA (5 μg) three times at 54 h, 30 h and 6 h prior to infection with HCoV-229E at
0.1 MOI for 1 h at 37 1C. At 12 h post-infection, cell lysates (bottom) and supernatants (upper) were harvested and subjected to western immunoblotting. Viral proteins were
detected with an anti-HCoV229E nucleocapsid (N) antiserum. N proteins from medium or cell samples were quantiﬁed by scanning N band density from immunoblots.
Ratios of N levels in medium to those in cells were determined and compared with the ratio of mock-infected samples. (B) HeLa cells transduced with shRNA targeting the
BST2 gene (HeLa/BST2-) or a non-targeting shRNA (shControl) were infected with HCoV-229E at 0.1 MOI. At 20 h post-infection, cell lysates (bottom) and supernatants
(upper) were harvested and subjected to western immunoblotting. (C) HeLa or HeLa/BST2-cells were transfected with the HIV-1 virus-producing vector NL4.3delVpu. At 48 h
post-transfection, cells and supernatants were collected, prepared, and analyzed by western immunoblotting. Viral proteins were detected with an anti-HIV-1 p24CA
monoclonal antibody. (D) A549 cells were infected with HCoV-229E at 0.1 MOI for 1 h at 37 1C. Cells were treated twice with the indicated concentrations of IFNα at 1 h and
24 h post-infection. At 36 h post-infection, cell lysates (bottom) and supernatants (upper) were harvested and subjected to western immunoblotting. Virus titers were
determined by plaque assays of A549 cells. nn, pr0.01. (E) A549 cells were infected with HCoV-229E at the indicated MOIs (lanes 2–5) or treated with IFNα (10,000 U/ml).
At 24 h post-infection, cells were collected and analyzed by western immunoblotting. (F) A549 cells were transfected with BST2-speciﬁc siRNA twice (at 1 h and 24 h)
following infection with HCoV-229E at 5.0 MOI for 1 h at 37 1C. Cells were treated twice with the indicated concentrations of IFNα at 4 h and 28 h post-infection. At 48 h
post-infection, cell lysates and supernatants were harvested and subjected to Western immunoblotting. Viral N proteins from medium or cell lysate samples were quantiﬁed
by scanning N band densities from immunoblots. The ratios of N levels in medium to those in cells were determined and normalized to the group without siRNA transfection
and IFN treatment (lane 4). The lower blot was derived from the upper blot by extending the exposure.
S.-M. Wang et al. / Virology 449 (2014) 287–296288
treatment enhanced BST2 expression (Fig. 1D, lane 3), which is
associated with a decrease in infectious progeny virus production
(lane 3 vs. lane 2).
To ﬁnd out if BST2 expression is induced by infections, we
inoculated A549 cells with HCoV-229E at different MOIs. Results
indicate barely detectable BST2 following HCoV-229E infection
(Fig. 1E). To determine if the IFNα-induced decrease in HCoV-229E
egress was due to BST2-triggered restrictions, we transiently
transfected HCoV-229E-infected A549 cells with BST2-speciﬁc
siRNA following IFNα treatment. Results indicate that BST2 knock-
down is capable of elevating HCoV-229E levels in supernatants
when normalized to cell-associated N levels (Fig. 1F, lane 7 vs.
lane 5). Similar results from independent experiments were
observed. BST2 expression in A549 cells was barely induced by
IFNα following HCoV-229E infection (Fig. 1F, lane 5 vs. lane 2),
suggesting that HCoV-229E counteracts the capability of IFNα to
induce BST2 expression or expresses certain factors against BST2.
IFNα does not signiﬁcantly enhance BST2 expression in HCoV-
229E-infected cells to restrict virus egress—in other words, the
effect of BST2 knockdown on virus egress enhancement is mar-
ginal. According to these data, it is difﬁcult to conclude whether
HCoV-229E egress is signiﬁcantly restricted by IFNα-induced BST2.
Our observation of a noticeable reduction in virus egress following
IFNα treatment (Fig. 1D) could be due, at least in part, to the time
of sample analysis (see “Discussion” section).
BST2 knockdown exerts no signiﬁcant effects on HCoV-229E entry
To further determine whether BST2 affects HCoV-229E replica-
tion, we assayed HCoV-229E growth kinetics in BST2 knockdown
HeLa cells (HeLa/BST2-). HeLa cells with or without BST2 knock-
down were inoculated with HCoV-229E at 0.1 MOI. Virus titers at
various times post-infection were determined by A549 cell plaque
assays. At 10 h post-infection and later, HeLa cells produced viral
titers at levels signiﬁcantly lower than HeLa/BST2- (Fig. 2A).
Between 7 and 9 h post-inoculation, HeLa/BST2- cells produced
higher virus titers, but not at a statistically signiﬁcant level. Plaque
morphologies of A549 cells infected with virions released from
HeLa/BST2- or HeLa cells were similar (data not shown). However,
we repeatedly observed that the sizes of viral plaques on HeLa/
BST2‐ cells were larger than those on HeLa cells following HCoV-
229E infection, despite the lack of major differences in plaque
numbers between the two cell types (Fig. 2B). Larger plaque sizes
observed on HeLa/BST2‐ cells were likely the result of the spread-
ing of nascent progeny virions to adjacent cells rather than
increased susceptibility to HCoV-229E infection. To verify the lack
of major impacts of BST2 knockdown on HCoV-229E susceptibility
or entry, we examined viral protein expression in both HeLa/BST2-
and HeLa cells at various times post-HCoV-229E infection.
As shown in Fig. 3A, HeLa/BST2- and HeLa cells had approximately
equal numbers of ﬂuorescent-positive viral nucleocapsid protein
cells at 4 h post-infection. However, at 6 h post-infection and later
there was a much larger number of ﬂuorescent-positive HeLa/
BST2- cells compared to HeLa cells—an increase likely due to the
spread of nascent progeny virions. These results were conﬁrmed
by immunoﬂuorescence microscopy (Fig. 3B). Combined, the data
suggest that BST2 knockdown does not signiﬁcantly affect HeLa
cell susceptibility to HCoV-229E, but markedly affects progeny
virus yields.
HCoV-229E virus particles are tethered at cell surfaces
The above ﬁndings reﬂect low-MOI infections; we also ran tests
to determine if the same ﬁndings occurred under high-MOI
conditions. As shown in Fig. 4A, HeLa/BST2‐ cells produced larger
quantities of progeny virions compared to HeLa cells regardless of
MOI. The ﬁnding that HeLa cells produced a relatively low level of
N was likely due to a portion of those cells not being infected, in
part because of decreased virus spreading in the presence of BST2
(Fig. 3). Another possibility is that viral proteins were not fully
expressed at 12 h post-infection. To determine whether BST2
restriction of HCoV-229E occurs in the same manner as in other
enveloped viruses (i.e., whether virus particles are tethered at the
cell surface), we ﬁxed HeLa and HeLa/BST2‐ cells and observed
them with a scanning electron microscope at 12 h post-infection.
As shown in Fig. 4B and C, numerous clusters consisting of
between 2 and 20 virus particles were found on HeLa cell surfaces.
In contrast, most of the virus particles found on HeLa/BST2‐ cell
surfaces were singular and scattered. When treated with the
protease subtilisin (which triggers the release of cell surface-
associated HIV-1 virions by cleaving BST2 (Neil et al., 2007)),
much larger quantities of HCoV-229E or HIV-1 (control) virions
were recovered in supernatants (Fig. 4D, lanes 5–6 vs. lanes 3–4).
No signiﬁcant increases in virion quantity were found in HeLa/
BST2- culture supernatant following subtilisin treatment (Fig. 4D,
lane 12 vs. lane 14). We also observed that larger amounts of
HCoV-229E virions were recovered from HeLa culture medium
than from HeLa/BST2- cell culture medium following subtilisin
treatment, suggesting that the HeLa cells had larger quantities of
virions trapped at the cell surface (Fig. 4D, lane 6 vs. lane 14). This
result is compatible with SEM analysis data showing much smaller
quantities of HCoV-229E virions found on the surfaces of HeLa/
Fig. 2. BST2 restricts HCoV-229E replication. (A) HCoV-229E growth kinetics in
HeLa and HeLa/BST2 cells. HeLa cells with or without BST2 knockdown were
infected with HCoV-229E at 3 MOI. At 7 to 12 h post-infection, serially diluted
supernatants were used to infect A549 cells, and viral titers were determined by
standard plaque assays (n, pr0.05; nn, pr0.01). (B) Plaque morphologies of HCoV-
229E. HeLa, and HeLa/BST2- cells grown in dish plates were inoculated with HCoV-
229E at 0.1 MOI for 1 h. Culture dishes were then washed twice with PBS and
gently overlaid with 2–4 ml of 0.5% agarose. After ﬁve days of incubation, plaques
were visualized by staining with 0.03% neutral red.
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BST2‐ cells (Fig. 4B); it also provides support for the proposal that
HCoV-229E is readily released from cells in the absence of BST2.
Combined, these ﬁndings support the assumption that BST2
strongly inhibits HCoV-229E progeny virion production by physi-
cally tethering budding virions to cell surfaces.
HCoV-229E virions associate with BST2
Since coronavirus particle budding occurred at ER/Golgi com-
partments, it is likely that the budding virions were tethered to
vesicle membranes by BST2, and therefore could not be released
from cell surfaces post-exocytosis at the plasma membrane. To test
this idea, we performed transmission electron microscopy ana-
lyses of HCoV-229E-infected cells. Our results indicate much larger
quantities of virions on HeLa cell surfaces compared to HeLa/BST2‐
cell surfaces (Fig. 5A vs. Fig. 5C), which agrees with our SEM data
(Fig. 4B). In addition, we consistently observed that virions in HeLa
intracellular vesicles tended to cluster at membrane surfaces
(Fig. 5B), whereas virions in HeLa/BST2‐ intracellular vesicles were
distinctly separate from each other and/or not closely associated
with cell membranes (Fig. 5D). Results from the immunogold
labeling of BST2 indicate the presence of BST2 molecules between
virions and/or between virions and cell membranes (Fig. 5E–G,
arrows), giving further support to the proposal that BST2 tethers
virions to cell membranes, and suggesting that HCoV-229E virions
can be linked via BST2.
HCoV-229E infection downregulates BST2 expression level
and rescues HIV-1 egress
Since viruses such as HIV-1 (Habermann et al., 2010) and
inﬂuenza (Mangeat et al., 2012) are capable of downregulating
BST2 expression levels on cell surfaces, we looked at whether
HCoV-229E infection has a similar capability. Flow cytometry
results indicate that cell surface BST2 levels were signiﬁcantly
lower following HCoV-229E infection at 5 MOI (Fig. 6A). Further,
confocal microscopy observations show that BST2 signal on the
plasma membranes of HCoV-229E-infected cells was noticeably
lower compared to uninfected cells (Fig. 6B). Consistent with the
results shown in Fig. 4A, ﬂow cytometry and immunoﬂuorescence
Fig. 3. BST2 knockdown has no signiﬁcant effects on HCoV-229E entry. (A) HeLa and HeLa/BST2 cells were inoculated with HCoV-229E at 0.1 MOI for 1 h at 37 1C. At each
indicated time, cells were ﬁxed and expressed viral nucleocapsid (N) proteins were detected with a rabbit anti-N antibody and a secondary FITC-conjugated anti-rabbit
antibody. Cells were then analyzed by ﬂow cytometry. Percentages of infected cells were determined by dividing the number of FITC-positive cells by the number of total
cells and multiplying by 100. (B) HeLa and HeLa/BST2‐ cells were infected with HCoV-229E at either 0.1 or 2 MOI. At 4, 6, or 12 h post-infection, cells were ﬁxed, probed with
a primary anti-229E N antibody and a secondary rhodamine-conjugated anti-rabbit antibody, and observed using a laser confocal microscope. Nuclei were stained with DAPI
(blue). Mock-infected cells or cells not exposed to the primary antibody yielded no signal (data not shown).
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analyses indicate that HCoV-229E infection at a lower MOI did not
result in signiﬁcant change in overall or surface BST2 expression
levels in HeLa cells (data not shown).
Given the association between efﬁcient HIV-1 egress and BST2
downregulation, it is possible that HCoV-229E is capable of
enhancing HIV-1 NL4.3delVpu release from HeLa cells by counter-
acting BST2 anti-viral activity. To test this possibility, we trans-
fected HeLa cells with a NL4.3delVpu expression vector prior to
HCoV-229E infection. We observed a signiﬁcant reduction in BST2
expression level tied to a 1.7-fold increase in NL4.3delVpu virus
particle production (Fig. 6C). Combined, these results suggest that
HCoV-229E infection leads to BST2 downregulation in HeLa cells,
thus contributing to greater Vpu-defective HIV-1 egress.
Discussion
Our main ﬁnding is that BST expression results in a signiﬁcant
decrease in progeny virus production. This is in agreement with the
notion that BST2 is a major component of innate immunity against
enveloped virus replicative infections. Both transient and stable
expression of BST2 knockdown resulted in the marked enhancement
of HCoV-229E progeny virus titer quantities. Electron microscope
observations indicate an associationwith virus particle clusters at cell
surfaces in the presence of BST2 (Figs. 4 and 5). Immunogold labeling
results indicate that BST2 molecules enhanced the linking of virions
to each other or to cell membranes (Fig. 5), suggesting that HCoV-
229E virions are restricted to membranes by BST2 during budding
in ER/Golgi compartments. The primary site of BST2 antiviral activity
is thought to be the cell surface, where many viruses acquire
their envelopes by directly budding from the plasma membrane
(Le Tortorec et al., 2011; Swiecki et al., 2013). However, some
enveloped viruses such as herpesviruses (which complete their ﬁnal
envelopment by obtaining membranes from TGN and/or endosomal
compartments and egress via exocytosis), are also subject to BST2
restrictions Mansouri et al., 2009; Mettenleiter, 2002). Results from
one recent study suggest that BST2 can moderately restrict the
release of hepatitis C virus (HCV), whose assembly takes place in
the ER, and whose release from cells occurs via secretory pathways in
a fashion similar to that of coronaviruses (Dafa-Berger et al., 2012;
Jones and McLauchlan, 2010). It is possible that virions linked to
vesicle membranes via BST2 association are retained on cell surfaces
following the exocytotic fusion of virion-containing vesicles with
plasma membranes. This ﬁnding, plus the inhibition of enveloped
virus budding at the plasma membrane, suggests that BST2 is also
capable of inhibiting virus budding at intracellular membranes.
While Dafa-Berger et al. (2012) report that BST2 restricts
hepatis C virus egress, they also found that (a) IFN-induced BST2
expression levels in Huh-7.5 cells remained unchanged when cells
were infected with HCV followed by IFN treatment, and (b) HCV
Fig. 4. BST2 restricts virion release by retaining virus particles on cell surfaces. (A) BST2 restricts HCoV-229E progeny virion release at different MOIs. HeLa and HeLa/BST2
cells were infected with HCoV-229E at 0.01, 0.05 or 5 MOI. At 12 h post-infection, cell lysates (bottom) and supernatants (upper) were harvested and subjected to western
immunoblotting. HCoV-229E N was detected with anti-HCoV-229E N antiserum, and BST2 proteins were probed with rabbit anti-BST2 antiserum. (B) Scanning electron
microscopy (SEM) analyses of HCoV-229E-infected cells. HeLa or HeLa/BST2 cells were infected with HCoV-229E at 0.1 MOI. At 12 h post-infection, cells were prepared and
observed under a scanning electron microscope. The high-power view in the inset shows cell surface-associated virions. Bars, 1 μM. (C) Classiﬁcation of virus particles
tethered to cell surfaces. Cell surface-associated virus particles were counted in randomly selected 50 view-ﬁelds of SEM images. Virus particles were classiﬁed as 1, 2–20, or
420 virus particles per cluster. (D) Cell surface-associated virions become detached following subtilisin treatment. HeLa and HeLa/BST2 cells were transfected with
NL4.3delVpu or infected with HCoV-229E at 0.1 MOI. At 24 h post-infection or post-transfection, supernatants were collected and cells were split equally into two dish plates.
At 4 h, culture mediumwas removed, washed twice with PBS, and incubated with PBS containing subtilisin (1 mg/ml) for 10 min at 37 1C. Supernatants were then harvested
and pelleted through 20% sucrose cushions. Pellets and cell lysates were subjected to western immunoblot analyses. HIV-1 was detected with an anti-HIV-1 p24CA antibody,
and HCoV-229E was determined with an antibody against the HCoV-229E nucleocapsid (N).
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infection had little impact on BST2 level in a stable BST2-
expressing Huh-7.5 cell line, suggesting that HCV lacks the
necessary mechanism or mechanisms to counteract BST2. Our
results indicate that HCoV-229E infections can signiﬁcanly reduce
BST2 expression and enhace NL4.3delVpu virion release (Fig. 6),
suggesting that HCoV-229E may express anti-BST2 factors. Further,
the high BST2 expression level induced by IFNα in mock-infected
A549 cells was not observed when cells were infected with HCoV-
229E (Fig. 1F, lane 2 vs. lane 5). We have no direct evidence
suggesting that HCoV-229E infection can signiﬁcanly downregu-
late IFNα-induced BST2; however, our data suggest that HCoV-
229E-infected A549 cells can counteract the ability of IFNα to
trigger BST2 expression. This scenario is similar to the intial phase
of HCoV-229E infection of respiratroy tract cells, which express
very low or undetectable levels of basal BST2 (Erikson et al., 2011).
Once cells are infected by HCoV-229E, BST2 expression is down-
regulated, even in the presence of subsequently induced IFN. As a
result, HCoV-229E egress is unrestricted.
We consistently observed that HeLa cell infections with HCoV-
229E at low MOIs (0.01–1.0) did not trigger signiﬁcant changes in
total or cell surface BST2 expression 24 h post-infection. However,
total or surface BST2 levels in HeLa cells were markedly reduced at
an infection MOI of 5.0 (Fig. 4A, lane 5 and Fig. 6). This suggests
that BST2 downregulation following HCoV-229E infection is MOI-
dependent. Bampi et al. have reported the mediation of BST2
degradation by Sendai virus (SeV) glycoproteins; however, sig-
niﬁcant total BST2 downregulation in HeLa cells at 24 h post-
infection requires inoculation at 20 MOI (Bampi et al., 2013). They
therefore concluded that BST2 degradation requires a threshold of
viral proteins. It is likely that at shorter time periods post-infection
and/or at low MOIs, BST2 antagonist expression by HCoV-229E is
insufﬁcient to counteract the effects of BST2. Since HCoV-229E
egress becomes unrestricted after longer infection periods, the
elevation of virus egress by BST2 knockdown becomes unneces-
sary. This may explain, at least in part, why we did not observe
signiﬁcant improvement in HCoV-229E egress due to the siRNA
knockdown of BST2 at 48 h post-infection (Fig. 1F); at this point,
IFNα-induced BST2 may have been neutralized by HCoV-229E.
In contrast, the impact of IFNα-induced BST2 on virus egress was
signiﬁcant in samples analyzed 24 h post-infection (Fig. 1D).
While BST2 signiﬁcantly blocks HCoV-229E progeny virus
release, it does not completely block HCoV-229E replication.
BST2 is one component of innate immune response in the form
of restricting enveloped virion release (Sauter et al., 2010). How-
ever, many viruses have evolved speciﬁc antagonists to counteract
BST2 anti-viral activity—examples include HIV-1 Vpu, HIV-2 Env,
simian immunodeﬁciency virus, Nef and Env, Ebola and Sendai
virus GP, and Kaposi's sarcoma-associated herpesvirus (KSHV) K5
(Gupta et al., 2009; Jia et al., 2009; Kaletsky et al., 2009;
Le Tortorec and Neil, 2009; Mansouri et al., 2009; Neil et al., 2008;
Pardieu et al., 2010; Bampi et al., 2013). Our ﬁnding that HCoV-229E
infection leads to markedly reduced BST2 expression levels similar to
those observed in HIV-1 infections suggests that some HCoV-229E
factors are capable of triggering BST2 downregulation. In the case of
Fig. 5. BST2 associates with HCoV-229E virions. HeLa (panels A, B and E–G) or HeLa/BST2- cells (panels C and D) were infected with HCoV-229E at 0.1 MOI. At 12 h post-
infection, cells were ﬁxed, prepared, and viewed with a transmission electron microscope. BST2 was probed with rabbit anti-BST2 antiserum, followed by a secondary 10 nm
gold conjugated anti-rabbit antibody (panels E–G). Immunogold particles were barely detectable in HeLa/BST2- cells and in HeLa cells not exposed to the primary antibody
(data not shown). Arrows indicate virions found on cell surfaces or in vesicles. Bars, 200 nm.
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Fig. 6. HCoV-229E infection downregulates BST2 expression levels on cell surfaces and enhances HIV-1delVpu egress. (A) HeLa cells were mock-infected or infected with
HCoV-229E at 5 MOI. At 18 h post-infection, cells were ﬁxed and probed with a rabbit anti-BST2 antibody prior to the permeabilization of cell membranes, followed by a
secondary FITC-conjugated anti-rabbit antibody. After the permeabilization of cell membranes, HCoV-229E N proteins were probed with a primary anti-HCoV-229E N
antibody and a secondary phycoerythrin-conjugated goat anti-rabbit antibody. Cells were then analyzed by ﬂow cytometry. Median ﬂuorescence intensity (MFI) values of
HCoV-229E-infected samples were compared to those of mock-infected samples. (B) HeLa cells were infected with HCoV-229E at 0.1 MOI. At 18 h post-infection, cells were
ﬁxed and permeabilized. BST2 proteins were detected with a mouse anti-BST2 antibody followed by a secondary FITC-conjugated anti-mouse antibody. HCoV-229E N
proteins were probed with a primary anti-HCoV-229E N antibody and a secondary rhodamine-conjugated goat anti-rabbit antibody. BST2 signal (arrows) decreased on the
surfaces of HCoV-229E-infected (red) cells. (C) HeLa cells were transfected with NL4.3delVpu. At 4 h post-transfection, cells were replated onto two dish plates and either
mock-infected or infected with HCoV-229E at 5 MOI. At 24 h post-infection, cells and culture supernatants were collected and subjected to western immunoblot analysis.
Ratios of total Gag protein level in the medium versus cell were calculated by scanning p24gag-associated band densities from immunoblots. The ratio of infected group was
normalized to that of mock-infected group.
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SARS-CoV, IFN expression is suppressed following infection
(Narayanan et al., 2008); this may promote virus spreading due to
its inability to trigger BST2 expression. However, SARS is considered
a systemic disease involving many organs (Holmes, 2003) that
constitutively express BST2 (Erikson et al., 2011). It remains to be
determined whether SARS-CoV virion release is also restricted by
BST2, and whether coronaviruses (including SARS-CoV) have evolved
strategies to oppose BST2 anti-viral activity.
In conclusion, our evidence suggests that BST2 is capable of
restricting HCoV-229E release from cells by tethering nascent
progeny virions to cell surfaces. This also supports the assumption
that the release of enveloped viruses whose budding takes place at
the plasma membrane or in an intracellular compartment is
subject to restriction via BST2.
Materials and methods
Virus, cell culture and transfection
Human coronavirus 229E (HCoV-229E) were propagated in
A549 or HeLa cells. 293T, HeLa and A549 cells were maintained
in Dulbecco's modiﬁed Eagle's medium (DMEM) supplemented
with 10% fetal bovine serum. For transfection, conﬂuent cells were
trypsinized, split 1:10, and seeded onto 10 cm dish plates 24 h
before transfection. Cells were transfected with 20 μg of plasmid
DNA by the calcium phosphate precipitation method, with the
addition of 50 μM chloroquine to enhance transfection efﬁciency.
For cotransfection, 10 μg of each plasmid was used. To transfect
HeLa cells with BST2-speciﬁc siRNA (BST2 siRNA), siRNA was
mixed with Lipofectamine 2000 (Invitrogen) at a ratio of 1 μg to
2.5 μl, the transfection procedure was performed according to the
manufacture's protocols.
Construction of plasmids and stable BST2 knockdown cell lines
To construct the HIV-1 Vpu deletion mutant (NL4.3delVpu), we
employed a PCR-mediated mutagenesis method (Sambrook and
Russell, 2001) to introduce two consecutive stop codons in-frame
at the N-terminal Vpu region. The primer sequence used to create
the delVpu mutation is 5′-ACATGTAATGTACAACCTATAATAG-3′. The
delVpu mutation construct was subcloned into NL4.3Env-which has
the env coding sequence (BglII-nt.7031 to BglII-nt. 7611) partially
deleted. Constructs were conﬁrmed by restriction enzyme diges-
tion and DNA sequencing. Small interfering RNA (siRNA) sequence
(5′-CCAggUCUUAAgCgUgAgAAUC-3′) directed against BST-2 was
synthesized by MDBio, Inc. To establish BST2 stale knockdown cell
lines, pseudotyped lentiviruses containing the BST2 shRNA were
generated in 293T cells. Virus-containing supernatants then were
used to infect HeLa cells. BST2 knockdown cell lines were selected
with puromycin (3 μg/ml) and screened with western immunoblot-
ting. The lentivirus-based shRNA construct targeting the BST2 gene,
NM_004335.2-432s1c1 and lentivirus package plasmids including
pCMVDR8.91 and pMD.G (VSV-G) were purchased from National
RNAi Core Facility Platform (NRC), Academia Sinica, Taiwan.
Western immunoblot
Culture medium from transfected or infected cells was ﬁltered
(0.45-μm pore size) and centrifuged through 2 ml of 20% sucrose
in TSE (10 mM Tris–HCl [pH 7.5], 100 mM NaCl, 1 mM EDTA) plus
0.1 mM phenylmethylsulfonyl ﬂuoride (PMSF) at 4 1C for 40 min at
274,000 g (SW41 rotor at 40,000 rpm). Viral pellets were sus-
pended in IPB (20 mM Tris–HCl [pH 7.5], 150 mM NaCl, 1 mM
EDTA, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X-100, 0.02%
sodium azide) plus 0.1 mM PMSF. Cells were collected in 1 ml
phosphate-buffered saline (PBS), and pelleted at 3000 rpm for
5 min. Cell pellets were resuspended in 250 μl of IPB plus 0.1 mM
PMSF prior to microcentrifugation at 4 1C for 15 min at 13,700 g
to remove cell debris. Either supernatant or cell samples were
mixed with equal volumes of 2 sample buffer (12.5 mM Tris–HCl
[pH 6.8], 2% SDS, 20% glycerol, 0.25% bromophenol blue) and 5%
β-mercaptoethanol and boiled for 5 min. Samples were subjected
to SDS-PAGE and electroblotted onto nitrocellulose membranes
that were subsequently blocked with 5% non fat milk in Tris-
buffered saline containing 0.05% Tween 20 (TBST), followed by
incubation with the primary antibody in 5% non fat milk-TBST on a
rocking platform for 1 h at room temperature. Membranes were
then washed three times for 10 min each with TBST and rocked for
30 min with the secondary antibody in 5% non fat milk-TBST. Blots
were again washed three times in TBST for 10 min each, followed
by enhanced chemiluminescence (ECL) to detect membrane-
bound antibody-conjugated enzyme activity.
To detect membrane-bound HCoV-229E N or HIV-1 Gag pro-
teins, we used an anti-HIV-1 p24CA (mouse hybridoma clone 183-
H12-5C) monoclonal antibody or a rabbit anti-HCoV229E N serum
as the primary antibody. BST2 was detected with a human BST2
mouse antiserum (ab88523, Abcam) or rabbit antiserum (Miyagi
et al., 2009). Our secondary antibody was either a rabbit anti-
mouse or donkey anti-rabbit (HRP)-conjugated antibody. Manufac-
turer's protocols were followed for HRP activity detection (Pierce).
Plaque assay
Serial dilutions (10-fold) of the harvested culture mediumwere
used to infect subconﬂuent monolayers of A549 or HeLa cells
grown in 6-well culture plates. Plates were incubated at 37 1C for
one hour with gentle rocking every 15 min. Plates then were
washed twice with PBS following removal of the culture medium.
About 2 to 5 ml of 0.5% agarose were overlaid onto the monolayer
cells. After 5 days of incubation, 0.03% neutral red solution was
added to plates to visualize the plaque formation.
Laser scanning immunoﬂuresecne microscopy and ﬂow cytometry
HeLa or HeLa/BST2 cells were infected with HCoV-229E at a
0.1 or 2 MOI for 1 h at 37 1C. At 4 to 18 h post-infection, cells were
permeabilized at room temperature for 10 min in acetone following
ﬁxation with 3.7% formaldehyde at 4 1C for 20 min. Samples were
incubated with the primary antibody for 1 h and with the secondary
antibody for 30 min. Following each incubation, samples were washes
three times with DMEM/calf serum. Primary antibody was an anti-
BST2 or anti-HCoV-229E N antibody. A goat anti-rabbit or rabbit anti-
mouse FITC-conjugated, phycoerythrin-conjugated, or rhodoamine-
conjugated antibody served as the secondary antibody. Cell surface
BST2 was probed prior to the permeabilization of cell membranes.
Images were observed by a laser scanning confocal microscope
(OlympusFluoview FV10i). For ﬂow cytometric analysis, cells were
detached from dishes with 0.05% trypsin/EDTA prior to ﬁxation and
permeabilization. Human BST2 or HCoV-229E N proteins were probed
as described above. Cells were analyzed using a ﬂow cytometer (BD
FACSCanto II).
Scanning or transmission electron microscopy
Cells grown on cover glasses were ﬁxed with 2.5% glutaralde-
hyde (in 0.1 M cacodylate buffer pH 7.4) for 2 h, washed with 0.1 M
cacodylate buffer pH 7.4 three times, and ﬁxed again with
1% osmium tetraoxide (OsO4) (in 0.1 M cacodylate buffer pH7.4)
for 1 h. Samples then were dehydrated by sequential incubation
with 25%, 50%, 70%, 85%, 95% and 100% ethanol for 10 min each,
dried in a critical point dryer (Samdri-PVT-3B, Tousimis Research,.
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Rockville, MD), coated with gold (Jeol JFC-1200), and viewed with a
scanning electron microscope (Jeol JSM-7600 F). Images were
collected at 10,000 and 20,000 . For transmission electron
microscopy (TEM) analysis, cells were harvested 12 h post-
infection and ﬁxed in 0.1 M Cacodylate buffer containing 2.5%
glutaraldehyde, post-ﬁxed with 1% OsO4, dehydrated in ethanol
and embedded in Spurr resin. Ultrathin sections (70 nm-thick)
were cut with an ultramicrotome, stained with 5% uranyl acetate
and 0.4% lead citrate. For immunegold labeling of BST2 proteins,
samples were embedded in acrylic resin (LR White Resin, London
Resin Company) at 4 1C for 48 h following ethanol dehydration.
Ultrathin sections were incubated with an anti-BST2 rabbit serum
for 2 h and with a secondary 10-nm immunegold-conjugated
goat anti-rabbit IgG antibodies for 1 h. Samples were washed
with PBS tree times after each incubation, ﬁxed with 2% glutar-
aldehyde, stained, and viewed with a Joel JEM-2000 EX-II trans-
mission electron microscope. Images were collected at 20,000 ,
60,000 or 100,000 .
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